Clicky

Lineage Cell Therapeutics, Inc.(LCTX)

Description: Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.


Keywords: Biotechnology Life Sciences Biology Immunotherapy Stem Cell Cell Therapy Non Small Cell Lung Cancer Drug Delivery Osteoarthritis Degenerative Disease Human Diseases Stem Cell Therapy Dry Age Related Macular Degeneration Treatment Of Hiv Regenerative Medicine Advanced Therapy Orthopedic Diseases Lineage Cell Therapeutics

Home Page: www.lineagecell.com

LCTX Technical Analysis

2173 Salk Avenue
Carlsbad, CA 92008
United States
Phone: 442 287 8990


Officers

Name Title
Mr. Brian M. Culley M.A., M.B.A. CEO, Pres & Director
Mr. George A. Samuel III, J.D. Gen. Counsel & Company Sec.
Ms. Jill Ann Howe CFO & Principal Financial and Accounting Officer
Ioana C. Hone Director of Investor Relations
Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D. Sr. VP of Clinical & Medical Affairs
Ms. Brandi L. Roberts CPA, M.B.A. Consultant
Mr. William Annett Pres & CEO of OncoCyte Corp.
Dr. Rami Skaliter Chief Exec. Officer of Cell Cure Neurosciences Ltd.
Ms. Alexandra Hernandez Sr. Director of Fin. & Controller
Dr. Harold D. Waitz VP of Regulatory Affairs & Quality Control

Exchange: NYSE MKT

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.7774
Price-to-Sales TTM: 16.0768
IPO Date: 1992-03-06
Fiscal Year End: December
Full Time Employees: 57
Back to stocks